Fatigue

Hack The Box Redefines Cybersecurity Performance, Setting New Standards in the Cyber Readiness of Organizations

Retrieved on: 
torsdag, april 11, 2024
Investment, Glass, Crime, Box, Fatigue, Computer security, Organization, Knowledge, Risk management

The innovative Cyber Performance Center approach helps businesses present a united front against cybercrime by aligning cybersecurity and corporate goals.

Key Points: 
  • The innovative Cyber Performance Center approach helps businesses present a united front against cybercrime by aligning cybersecurity and corporate goals.
  • By matching processes and exercises to organizational outcomes it helps to align cybersecurity and business objectives.
  • "At Hack The Box, we believe cybersecurity readiness is not just a technical requirement but a company-wide imperative, involving people, technology, and processes", highlights Haris Pylarinos, Founder and CEO at Hack The Box.
  • Hack The Box is the only Cyber Performance Center that builds on three critical pillars:
    Continuous, gamified, hands-on upskilling from cybersecurity fundamentals to advanced scenarios.

Insights into CMGE (0302. HK) 2023 Financial Results: Rich Reserve of New Games Set to Drive Significant Business Growth

Retrieved on: 
måndag, april 8, 2024
HK, IP, The Fairly OddParents, Ecosystem, ChatGPT, GameWeek Magazine, Guosen Securities, AI, Will, IPS, Publishing, Entrepreneurship, Legend, Research, Animation, Growth, WeChat, Literature, TapTap, Three Kingdoms, Result, Tencent Video, Intellectual property, Culture, Research report, Television, Fatigue, Fire, Cao Cao, Music, Apple Store, IQIYI, Behavior, Battle Through the Heavens, Copywriting, Video game

HK), a game operator listed on the Hong Kong Stock Exchange, recently released its annual financial report for the year 2023.

Key Points: 
  • HK), a game operator listed on the Hong Kong Stock Exchange, recently released its annual financial report for the year 2023.
  • Co-published by CMGE and Tanwan Games, the game secured a license in July 2023 and initiated a reservation campaign in August, attracting over 6 million sign-ups.
  • Industry experts noted that one of the emerging opportunities in the game industry in 2023 was the rise of the mini-game market.
  • According to analysts, CMGE, a forerunner in IP games, possesses extensive IP reserves conducive to achieving high-quality and premium product-driven development.

Inceptio-Powered Autonomous Trucks Surpass 100 Million Kilometers in Safe Commercial Operations

Retrieved on: 
torsdag, maj 9, 2024
LTL, Express, HKEX, Safety, Way, SHE, OEM, Transport, L3, JD, Budweiser, Fatigue, Creativity, Foton, Drink, Algorithm, SF Express, Rail transport

SHANGHAI, May 9, 2024 /PRNewswire/ -- Inceptio Technology ("Inceptio," or the "Company"), an industry leading developer of autonomous driving technologies for heavy-duty trucks, today announced that heavy-duty trucks powered by the Inceptio Autonomous Driving System and its Truck Navigate-on-Autopilot (T-NOA) capabilities have surpassed the significant milestone of 100 million kilometers in safe commercial operations, reinforcing Inceptio's global leadership in the commercialization of autonomous trucks.

Key Points: 
  • SHANGHAI, May 9, 2024 /PRNewswire/ -- Inceptio Technology ("Inceptio," or the "Company"), an industry leading developer of autonomous driving technologies for heavy-duty trucks, today announced that heavy-duty trucks powered by the Inceptio Autonomous Driving System and its Truck Navigate-on-Autopilot (T-NOA) capabilities have surpassed the significant milestone of 100 million kilometers in safe commercial operations, reinforcing Inceptio's global leadership in the commercialization of autonomous trucks.
  • Inceptio-powered trucks surpassed 50 million kilometers of safe commercial operations in August 2023.
  • Over the course of the 100 million kilometers, a total of 1,864 drivers safely used Inceptio-powered L3 and L2+ trucks in their daily operations.
  • Inceptio has partnered with several leading Chinese truck manufacturers to pre-load mass produced trucks with the Inceptio Autonomous Driving System.

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
torsdag, maj 9, 2024
PFS, Sale, FDA, Azacitidine, Cancer, Research and development, Investment, ZF, IST, Nausea, Research, Hematology, KICKSTART, Fulvestrant, Insurance, AML, Artificial intelligence, Administration, ZFA, Science, Vomiting, COX, Patient, Fatigue, MNK, Effector, G&A, Assistant, Messenger, Acute myeloid leukemia, Cell, Interval (mathematics), Associate, Therapy, NSCLC, Breast cancer, Anemia, Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses were $5.3 million for the quarter ended March 31, 2024, compared to $6.6 million for the same quarter of 2023.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.1 million for the quarter ended March 31, 2024, compared to $2.9 million for the same quarter of 2023.
  • G&A expenses included approximately $0.6 million and $0.7 million of non-cash stock compensation expense in the quarters ended March 31, 2024, and 2023, respectively.
  • Other Expense: Other expense was $0.4 million and $0.5 million for the quarters ended March 31, 2024, and 2023, respectively.

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
FDA, CRR, DLBCL, Investment, Safety, Food, Nausea, Research, PTCL, Peripheral T-cell lymphoma, Thrombocytopenia, Insurance, Weight loss, Appetite, PTLD, Data, Dor, Patient, Fatigue, Diarrhea, SDD, Therapy, PMDA, Valganciclovir, Food and Drug Administration, SAN, Anemia, Pharmaceutical industry

We look forward to sharing additional data from Stage 1, which continue to mature, as well as initial results from Stage 2 in the third quarter of 2024.

Key Points: 
  • We look forward to sharing additional data from Stage 1, which continue to mature, as well as initial results from Stage 2 in the third quarter of 2024.
  • As of the February 7, 2024 data cutoff date, Nana-val demonstrated greater efficacy than nanatinostat alone and was generally well-tolerated.
  • Present Stage 1 + Stage 2 data (n=21) in the R/R EBV+ PTCL cohort in patients treated with Nana-val in the third quarter of 2024.
  • Initiate a dose-optimization cohort to confirm the RP2D as part of the study’s Phase 2 expansion by year-end 2024.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Retrieved on: 
torsdag, maj 9, 2024
FDA, Bone marrow, Mutation, Cell, Risk, Blood, News, Research, ERT, White blood cell, Glycogen storage disease, SRT, ALT, GBA1, White, European Medicines Agency, Brain, Enzyme replacement therapy, Regenerative Medicine Advanced Therapy, Therapy, Plasma, Patient, Mouse, Safety, Tissue, Glucocerebrosidase, Substantia nigra, Lysosome, Neuropsychological test, AAV, Dementia, PRIME, Fatigue, EMA, Drug development, Bone pain, Gaucher's disease, FACIT, Disease, Liver, Gene, Society, Standard of care, Annual general meeting, Pharmaceutical industry

LONDON, May 09, 2024 (GLOBE NEWSWIRE) --  Freeline Therapeutics today announced new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, showing substantial reductions in glucosylsphinogsine (lyso-Gb1), one of the best predictors of clinical response, in patients with persistently high levels despite years of treatment with currently approved therapies, as well as early signs of clinical improvements in bone marrow burden and fatigue. FLT201 continues to demonstrate a favorable safety and tolerability profile. These data are being showcased in a late-breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, Maryland.

Key Points: 
  • These data are being showcased in a late-breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, Maryland.
  • Reductions in lyso-Gb1 levels in the blood are highly correlated with substrate reduction in disease-affected tissues and positive clinical outcomes in Gaucher disease.
  • Currently approved treatments have made a significant difference for people with Gaucher disease, but there is not an existing cure.
  • Both the late-breaking oral presentation and the poster presentation are now available on the News & Events section of Freeline’s website.

JumpCloud Delivers Powerful New Features for Google Workspace and Google Cloud Customers

Retrieved on: 
torsdag, maj 9, 2024
Cloud, Insight, Glass, Risk, Google Cloud, MDM, Federated, JumpCloud, Partnership, Google Workspace, Environment, MFA, Fatigue, Apple, ID, Windows 10, Passwordless authentication, Organization, Mobile phone

LOUISVILLE, Colo., May 09, 2024 (GLOBE NEWSWIRE) -- JumpCloud Inc. today announced new features to help Google Workspace and Google Cloud customers get even more out of their JumpCloud on Google use.

Key Points: 
  • LOUISVILLE, Colo., May 09, 2024 (GLOBE NEWSWIRE) -- JumpCloud Inc. today announced new features to help Google Workspace and Google Cloud customers get even more out of their JumpCloud on Google use.
  • Three features in particular are designed specifically to help Google Cloud and Google Workspace customers:
    Passwordless access capabilities through JumpCloud GoTM that use biometrics for greater ease of use and provide phishing resistance.
  • Identity federation so customers can easily add device management to their environment using their Google Workspace credentials.
  • Today’s product announcements build on a year of JumpCloud momentum around the Google Cloud ecosystem.

Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

Retrieved on: 
onsdag, maj 8, 2024
MSD, PFS, FDA, Pfizer, MRNA, News, Atrophy, Weight loss, Doctor of Philosophy, Vaccine, University of Toronto, PFE, Medicinal chemistry, Medicine, Genome, Moderna, Diagnosis, AstraZeneca, Prevalence, GEJ, University, CPS, HER2, Food, OTC, IHC, Cachexia, Pneumococcal conjugate vaccine, Messenger, Quality of life, RSV, Patient, Facial muscles, Professor, Oncology, Trastuzumab, Research, Incidence, Fatigue, EPS, Neoplasm, MUSL, MRK, Tafamidis, Progression-free survival, PALM, PD-L1, COVID-19, Growth, Pharmaceutical industry

Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.

Key Points: 
  • Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.
  • The Cancer Cachexia market refers to the segment of the healthcare industry focused on addressing the multifaceted challenges associated with cachexia in cancer patients.
  • A report from Custom Market Insights projects that the global Cancer Cachexia Market is expected to record a CAGR of 5.1% from 2024 to 2033.
  • In 2024, the market size is projected to reach a valuation of USD 3.3 Billion.

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Retrieved on: 
onsdag, maj 8, 2024
Compass, Administration, Safety, Post-traumatic stress disorder, Nausea, Neuroscience, Trauma, The Institute, Psychology, Crying, Disability, Suicidal ideation, History, SDS, Mental health, Patient, Fatigue, Headache, Sunstone, Suicide, Diagnosis, Quality of life, CMPS, Pharmaceutical industry

“These results, with early and lasting improvement in symptoms following a single administration of COMP360, are highly encouraging,” said Dr.

Key Points: 
  • “These results, with early and lasting improvement in symptoms following a single administration of COMP360, are highly encouraging,” said Dr.
  • “These observations, even with a small, open-label study, suggest that COMP360 could provide a clinically meaningful benefit and substantially improve patient daily function and quality of life.
  • The well tolerated safety profile for COMP360 in patients with PTSD, with no serious adverse events observed, advance our understanding of potential applications of COMP360.
  • Compass previously announced 24-hour safety data from the study, which indicated that COMP360 was well-tolerated, with no treatment emergent serious adverse events.

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Retrieved on: 
tisdag, maj 7, 2024
Congress, University, Insulin, Glomerular filtration rate, Risk, Nephrotoxicity, JDRF, Immunosuppression, Death, Neurotoxicity, Viral, EGFR, Hair loss, Patient, Kidney transplantation, Fatigue, Hypertension, Toxicity, Quality of life, Calcineurin, Pharmaceutical industry

IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with a novel immunosuppression regimen including tegoprubart, the company’s novel anti-CD40L antibody, which is in development for the prevention of pancreatic islet cell transplant rejection in patients with type 1 diabetes. The study is being conducted by the research team at University of Chicago Medicine’s Pancreatic and Islet Transplant Program. Separately, the company reported updated data from its ongoing Phase 1b trial demonstrating tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated.

Key Points: 
  • The study is being conducted by the research team at University of Chicago Medicine’s Pancreatic and Islet Transplant Program.
  • Separately, the company reported updated data from its ongoing Phase 1b trial demonstrating tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated.
  • Eledon is supplying tegoprubart as a cornerstone component of the immunosuppressive regimen for trial participants and tegoprubart is being evaluated for the prevention of transplant rejection in the trial.
  • Eledon is currently conducting a Phase 1b trial ( NCT05027906 ), the Phase 2 BESTOW trial ( NCT05983770 ), and a Long-Term Safety and Efficacy extension study ( NCT06126380 ) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.